AbCellera Biologics (ABCL) News Today $2.67 -0.04 (-1.48%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period GSA Capital Partners LLP Has $629,000 Position in AbCellera Biologics Inc. (NASDAQ:ABCL)GSA Capital Partners LLP boosted its holdings in shares of AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) by 991.3% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 241,866 shares of the company's stock after acquirNovember 19 at 3:48 AM | marketbeat.comAbCellera Biologics Inc. (NASDAQ:ABCL) Position Trimmed by Baillie Gifford & Co.Baillie Gifford & Co. reduced its holdings in AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) by 41.1% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 12,894,703 shares of the company's stock after selling 9,016,311 shares during the quNovember 13, 2024 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Sees Strong Trading Volume - Should You Buy?AbCellera Biologics (NASDAQ:ABCL) Sees Unusually-High Trading Volume - What's Next?November 11, 2024 | marketbeat.comBloom Burton Has Negative Outlook for ABCL FY2024 EarningsAbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) - Stock analysts at Bloom Burton reduced their FY2024 earnings per share estimates for shares of AbCellera Biologics in a report issued on Tuesday, November 5th. Bloom Burton analyst D. Martin now anticipates that the company will post earningsNovember 8, 2024 | marketbeat.comAbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024November 7, 2024 | theglobeandmail.comAbCellera Biologics Inc. (NASDAQ:ABCL) Just Reported And Analysts Have Been Cutting Their EstimatesNovember 7, 2024 | finance.yahoo.comAbCellera Biologics (ABCL) Gets a Buy from Truist FinancialNovember 7, 2024 | markets.businessinsider.comFY2024 Earnings Estimate for ABCL Issued By Leerink PartnrsAbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) - Stock analysts at Leerink Partnrs lowered their FY2024 earnings per share (EPS) estimates for shares of AbCellera Biologics in a research note issued to investors on Tuesday, November 5th. Leerink Partnrs analyst P. Souda now expects that theNovember 7, 2024 | marketbeat.comAbCellera Biologics Third Quarter 2024 Earnings: Misses ExpectationsNovember 7, 2024 | finance.yahoo.comStifel Nicolaus Sticks to Their Buy Rating for AbCellera Biologics (ABCL)November 7, 2024 | markets.businessinsider.comAbCellera Biologics (ABCL) Receives a Hold from Benchmark Co.November 7, 2024 | markets.businessinsider.comAbCellera Biologics (NASDAQ:ABCL) Receives "Hold" Rating from BenchmarkBenchmark reaffirmed a "hold" rating on shares of AbCellera Biologics in a research report on Tuesday.November 5, 2024 | marketbeat.comQ3 2024 Abcellera Biologics Inc Earnings CallNovember 5, 2024 | uk.finance.yahoo.comAbCellera Biologics (NASDAQ:ABCL) Earns Buy Rating from Stifel NicolausStifel Nicolaus reissued a "buy" rating and set a $12.00 price target (down previously from $14.00) on shares of AbCellera Biologics in a research report on Tuesday.November 5, 2024 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Shares Gap Down After Earnings MissAbCellera Biologics (NASDAQ:ABCL) Shares Gap Down on Disappointing EarningsNovember 5, 2024 | marketbeat.comAbCellera Biologics Inc. (NASDAQ:ABCL) Q3 2024 Earnings Call TranscriptNovember 5, 2024 | msn.comAbCellera Biologics (NASDAQ:ABCL) Issues Earnings ResultsAbCellera Biologics (NASDAQ:ABCL - Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.17) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.03). AbCellera Biologics had a negative net margin of 463.77% and a negative return on equity of 13.40%. The firm had revenue of $6.51 million during the quarter, compared to analyst estimates of $8.95 million. During the same quarter in the previous year, the business earned ($0.10) EPS.November 5, 2024 | marketbeat.comAbCellera Biologics Reports Q3 2024 Financial ResultsNovember 5, 2024 | markets.businessinsider.comAbCellera Biologics Inc (ABCL) Q3 2024 Earnings Call Highlights: Navigating Challenges with ...November 5, 2024 | finance.yahoo.comAbCellera Biologics Expands Partnership and Advances PipelineNovember 5, 2024 | markets.businessinsider.comAbCellera Biologics Inc. (ABCL) Q3 2024 Earnings Call TranscriptNovember 4, 2024 | seekingalpha.comAbCellera Biologics Inc. 2024 Q3 - Results - Earnings Call PresentationNovember 4, 2024 | seekingalpha.comAbCellera Biologics Inc (ABCL) Q3 2024: Everything You Need To Know Ahead Of EarningsNovember 1, 2024 | finance.yahoo.comAbCellera Biologics (ABCL) Set to Announce Quarterly Earnings on MondayAbCellera Biologics (NASDAQ:ABCL) will be releasing earnings after the market closes on Monday, November 4, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=631907)October 28, 2024 | marketbeat.comAbCellera to Present at Upcoming Investor Conferences in November 2024October 22, 2024 | businesswire.comAbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024October 18, 2024 | theglobeandmail.comIs AbCellera Biologics Inc. (ABCL) the Penny Stock with the Biggest Upside Potential According to Analysts?October 16, 2024 | msn.comAbCellera Biologics (NASDAQ:ABCL) Shares Down 5% - Here's What HappenedAbCellera Biologics (NASDAQ:ABCL) Trading Down 5% - Here's What HappenedOctober 14, 2024 | marketbeat.comAbCellera: A Platform To Pipeline TransitionOctober 14, 2024 | seekingalpha.comAbCellera Biologics Inc. ABCL (U.S.: Nasdaq)October 11, 2024 | wsj.comAbCellera Biologics (NASDAQ:ABCL) Trading 5.2% Higher - Still a Buy?AbCellera Biologics (NASDAQ:ABCL) Shares Up 5.2% - What's Next?October 7, 2024 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comRenaissance Technologies LLC Boosts Stock Holdings in AbCellera Biologics Inc. (NASDAQ:ABCL)Renaissance Technologies LLC raised its stake in AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) by 16.0% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,728,603 shares of the company's stock after acquiring an additional 239,000September 28, 2024 | marketbeat.comAbCellera Biologics Inc. (NASDAQ:ABCL) Given Consensus Recommendation of "Moderate Buy" by BrokeragesAbCellera Biologics Inc. (NASDAQ:ABCL - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six ratings firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and five have assigned a buy ratinSeptember 28, 2024 | marketbeat.comAbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024September 26, 2024 | businesswire.comABCL Jan 2025 15.000 putSeptember 21, 2024 | ca.finance.yahoo.comABCL Jan 2025 25.000 putSeptember 21, 2024 | ca.finance.yahoo.comABCL Jan 2025 17.000 callSeptember 21, 2024 | ca.finance.yahoo.comCitizens Financial Group Inc. RI Invests $923,000 in AbCellera Biologics Inc. (NASDAQ:ABCL)Citizens Financial Group Inc. RI acquired a new stake in shares of AbCellera Biologics Inc. (NASDAQ:ABCL - Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 311,890 shares of the companSeptember 18, 2024 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Trading Up 6.7%AbCellera Biologics (NASDAQ:ABCL) Shares Up 6.7%September 17, 2024 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Shares Down 5.5% AbCellera Biologics (NASDAQ:ABCL) Shares Down 5.5%September 16, 2024 | marketbeat.comAbCellera Biologics (NASDAQ:ABCL) Sees Large Volume IncreaseAbCellera Biologics (NASDAQ:ABCL) Sees Unusually-High Trading VolumeSeptember 10, 2024 | marketbeat.comShould You Follow Insider Buying on This Biotech Penny Stock?September 8, 2024 | msn.comAbCellera Biologics (NASDAQ:ABCL) Hits New 1-Year Low at $2.39AbCellera Biologics (NASDAQ:ABCL) Sets New 12-Month Low at $2.39September 6, 2024 | marketbeat.comAbCellera Biologics Inc. (NASDAQ:ABCL) Receives Average Recommendation of "Moderate Buy" from AnalystsShares of AbCellera Biologics Inc. (NASDAQ:ABCL - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the six brokerages that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and five have assignSeptember 3, 2024 | marketbeat.comAbCellera Biologics Inc. (ABCL): The Best Multibagger Penny Stock of 2025?September 2, 2024 | finance.yahoo.comCarl Hansen Buys Handful Of Shares In AbCellera BiologicsAugust 31, 2024 | finance.yahoo.comAbCellera Biologics Inc. (ABCL): A Top Contender Among Canada’s Best Penny Stocks in 2024August 30, 2024 | msn.comAbCellera to Present at Upcoming Investor Conferences in SeptemberAugust 30, 2024 | finance.yahoo.comAbCellera Biologics Inc. (ABCL): A Top Contender Among Canada's Best Penny Stocks in 2024August 29, 2024 | msn.com Get AbCellera Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for ABCL and its competitors with MarketBeat's FREE daily newsletter. Email Address This Bull Market Indicator called NVDA at $116 (Ad)Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run… All you have to do is follow this link here ABCL Media Mentions By Week ABCL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ABCL News Sentiment▼1.620.46▲Average Medical News Sentiment ABCL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ABCL Articles This Week▼13▲ABCL Articles Average Week Get AbCellera Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for ABCL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MoonLake Immunotherapeutics News Today Agios Pharmaceuticals News Today Verona Pharma News Today PTC Therapeutics News Today Dyne Therapeutics News Today Bausch Health Companies News Today Edgewise Therapeutics News Today Merus News Today Xenon Pharmaceuticals News Today HUTCHMED News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ABCL) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AbCellera Biologics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AbCellera Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
